Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial

PURPOSE: Cancer cachexia is characterized by decreased body weight (mainly lean body mass [LBM]) and negatively impacts quality of life (QOL) and prognosis. Anamorelin (ONO-7643) is a novel selective ghrelin receptor agonist under development for treating cancer cachexia. METHODS: In this double-bli...

Descripción completa

Detalles Bibliográficos
Autores principales: Takayama, Koichi, Katakami, Nobuyuki, Yokoyama, Takuma, Atagi, Shinji, Yoshimori, Kozo, Kagamu, Hiroshi, Saito, Hiroshi, Takiguchi, Yuichi, Aoe, Keisuke, Koyama, Akira, Komura, Naoyuki, Eguchi, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917578/
https://www.ncbi.nlm.nih.gov/pubmed/27005463
http://dx.doi.org/10.1007/s00520-016-3144-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917578/
https://www.ncbi.nlm.nih.gov/pubmed/27005463
http://dx.doi.org/10.1007/s00520-016-3144-z

Ejemplares similares